Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Covi Vax (NRC-VACC-101) in Healthy Adults
NCT05128721Phase 1Unknown
- Start
- Nov 2021
- Primary completion
- Feb 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Covi Vax in coronavirus disease 2019 (COVID-19) (3 arms). Primary endpoints: Safety of NRC-VACC-101 Vaccine and Tolerability of NRC-VACC-101 Vaccine. Status: unknown.
02
Drugs
Covi Vax
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05128721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05128721.